

Applicant : Eric Kandel et al.  
U.S. Serial No.: 10/582,303  
PCT Filing Date: December 9, 2004  
Page 2

**Amendments to the Claims:**

Pursuant to 37 C.F.R. §1.121(c), this listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A method for treating a subject afflicted with a fear-related disorder comprising administering to the subject a therapeutically effective amount of a gastrin-releasing peptide receptor agonist.
2. (Original) The method of claim 1, wherein the subject is human.
3. (Original) The method of claim 1, wherein the fear-related disorder is a phobia.
4. (Original) The method of claim 1, wherein the fear-related disorder is chronic anxiety.
5. (Original) The method of claim 1, wherein the fear-related disorder is a panic attack.
6. (Original) The method of claim 1, wherein the fear-related disorder is post-traumatic stress disorder.
7. (Original) The method of claim 1, wherein the fear-related disorder is autism.
8. (Original) A method for inhibiting in a subject the onset of a fear-related disorder resulting from exposure to a

Applicant : Eric Kandel et al.  
U.S. Serial No.: 10/582,303  
PCT Filing Date: December 9, 2004  
Page 3

traumatic experience comprising administering a prophylactically effective amount of a gastrin-releasing peptide receptor agonist to the subject prior to and/or following the traumatic experience.

9. (Original) The method of claim 8, wherein the subject is human.
10. (Original) The method of claim 8, wherein the fear-related disorder is a phobia.
11. (Canceled)
12. (Original) The method of claim 8, wherein the fear-related disorder is a panic attack.
13. (Original) The method of claim 8, wherein the fear-related disorder is post-traumatic stress disorder.
14. (Original) The method of claim 8, wherein the agonist is administered to the subject prior to the traumatic experience.
15. (Original) The method of claim 14, wherein the traumatic experience is military combat.
16. (Original) The method of claim 8, wherein the agonist is administered to the subject after the traumatic experience.
17. (Original) The method of claim 16, wherein the traumatic experience is a physical assault.

Applicant : Eric Kandel et al.  
U.S. Serial No.: 10/582,303  
PCT Filing Date: December 9, 2004  
Page 4

18. (Canceled)

19. (Original) A nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide.

20. (Previously Presented) A bacterial artificial chromosome (BAC) comprising the nucleic acid of claim 19.

21-25. (Canceled)

26. (Previously Presented) A transgenic animal whose somatic cells have stably integrated therein a nucleic acid comprising a gastrin-releasing peptide gene, wherein the gene has inserted into it, either at its start or stop codon, a polypeptide-encoding sequence, wherein the polypeptide is not gastrin-releasing peptide, and wherein the polypeptide is specifically expressed in the animal's amygdale.

27. (Previously Presented) A method for producing a transgenic animal whose amygdaloid cells specifically express endogenous polypeptide, which method comprises introducing into an oocyte an exogenous DNA so that the exogenous DNA is stably integrated into the oocyte, and permitting the resulting oocyte to mature into a viable animal, wherein (a) the animal's somatic cells have the exogenous DNA stably integrated therein, (b) the exogenous DNA comprises a gastrin-releasing peptide gene, wherein the gene has

Applicant : Eric Kandel et al.  
U.S. Serial No.: 10/582,303  
PCT Filing Date: December 9, 2004  
Page 5

inserted into it, either at its start or stop codon, an exogenous polypeptide is not gastrin-releasing peptide, and (c) the exogenous polypeptide is specifically expressed in the animal's amygdale.

28. (New) The method of claim 8, wherein the fear-related disorder is chronic anxiety.